Roughly 115 million adults worldwide are estimated to have metabolic dysfunction-associated steatohepatitis, or MASH, a severe form of fatty liver disease that can quietly progress to cirrhosis, liver failure, and transplant. Until March 2024, when the FDA approved resmetirom (brand name Rezdiffra), there was no drug specifically cleared to treat it. Even now, treatment options remain thin, expensive, and limited to a narrow slice of patients.
That backdrop is what makes a new finding from the Medical University of South Carolina so striking. Researchers there have shown that formoterol, a cheap, off-patent beta-2 agonist that millions of people inhale daily for asthma, largely reversed advanced fatty liver damage in mice after just four weeks of treatment. The results, published in npj Metabolic Health and Disease in May 2026, were not even what the team was looking for. They stumbled onto the liver effect while studying the drug’s impact on damaged kidneys.
Now a randomized pilot trial in patients with diabetic kidney disease is already enrolling, and the investigators say liver-specific studies could follow if early human data hold up.
What the mouse study actually showed
Mice were fed a high-fat diet long enough to develop advanced steatosis, the heavy fat accumulation in liver cells that characterizes the early and middle stages of MASH. Researchers then administered formoterol systemically for four weeks. By the end of treatment, the fatty liver damage had largely resolved at the tissue, cellular, and functional levels.
The mechanism centers on mitochondrial biogenesis. Treated animals showed elevated levels of PGC1-alpha, a master regulator of new mitochondria production, along with increased electron transport chain components and higher mitochondrial counts in liver tissue. In practical terms, the drug appeared to push liver cells to build fresh, functional energy-producing machinery. With better mitochondria burning fuel efficiently, the accumulated fat cleared.
This was not a one-off signal. The same MUSC research group, led by principal investigator Joshua Lipschutz, had previously published peer-reviewed work showing that formoterol triggers the same mitochondrial repair pathway in kidney tissue, accelerating recovery from glomerular injury and modulating mitochondrial dynamics in the diabetic renal proximal tubule. The liver discovery, as the university described in a detailed summary of the research program, was a surprise byproduct of that kidney-focused work.
The consistency of the biological signal across organs is what caught attention: one drug, one mechanism, potentially multiple diseases.
The human trial exists, but it is not a liver trial
A prospective randomized pilot trial of formoterol is now listed on ClinicalTrials.gov under identifier NCT07022418. It is enrolling patients with diabetic kidney disease, not fatty liver disease. The posted trial record lists kidney endpoints only. There is no liver-specific outcome measure, no patient stratification for steatohepatitis, and no imaging or biopsy protocol designed to capture hepatic changes.
That distinction matters. Even if the kidney trial produces encouraging results, any liver signal that emerges would be incidental rather than prospectively measured. Regulators would not treat it as definitive evidence for a new indication. A dedicated liver trial, with biopsy-confirmed MASH patients, standardized imaging, and liver-specific biomarkers, would still be needed before formoterol could be considered a fatty liver therapy.
The university’s own communications, including a news release describing the mouse data, frame the liver finding as promising while explicitly listing dose, delivery route, durability, and safety as unresolved questions.
The dose problem no one has solved yet
Formoterol is typically inhaled at microgram-level doses calibrated to relax airway smooth muscle. The preclinical liver studies used systemic administration in mice, producing plasma drug levels that may differ substantially from what a standard inhaler delivers to a human body.
No published study has compared inhaled versus systemic routes for hepatic tissue exposure. If reaching meaningful drug concentrations in the liver requires oral or injectable dosing, the safety calculus changes. Beta-2 agonists at higher systemic exposures can cause tremor, tachycardia, and electrolyte disturbances. These side effects are minimal with inhaled delivery but could become significant at doses needed to affect liver tissue. Until dose-finding studies in humans are completed, the gap between “works in mice” and “safe and effective in people” remains wide open.
Where formoterol fits in a changing treatment landscape
The MASH field has shifted rapidly. Resmetirom, the first FDA-approved drug for the condition, targets a thyroid hormone receptor pathway to reduce liver fat and inflammation. Several other candidates in late-stage trials attack fibrosis, metabolic signaling, or gut-liver axis dysfunction through entirely different mechanisms. Formoterol’s apparent focus on mitochondrial repair could make it complementary to these approaches, but it could also interact with other pathways in unpredictable ways.
Combination regimens may eventually prove more effective than any single drug, yet each new pairing raises fresh safety and interaction questions that only carefully designed trials can answer. Where formoterol might slot in, whether as a standalone therapy, an add-on, or a treatment for patients who cannot access or tolerate newer drugs, is a question that sits well beyond what mouse data can resolve.
Why this is not just another “mouse study cures disease” story
What separates this finding from the typical preclinical headline is the drug’s regulatory status. Formoterol is already approved, manufactured at scale, and available as a generic for a fraction of the cost of newer MASH therapies. If a viable dose and route for liver treatment can be identified, the path to clinical use would skip years of toxicology testing and manufacturing development that new molecules require.
That practical advantage is real. It does not, however, eliminate the need for controlled human trials demonstrating both safety and efficacy in liver disease specifically. The peer-reviewed evidence so far, a single mouse model published in a Nature Portfolio journal plus consistent kidney data from the same group, builds a coherent mechanistic story. It does not yet establish clinical benefit for human livers.
Durability is another blank. The mouse study ran four weeks. Whether the fat-clearing effect persists after treatment stops, or whether long-term dosing introduces new toxicity in already-stressed liver tissue, has not been tested. MASH in humans develops over years and typically coexists with obesity, type 2 diabetes, and cardiovascular disease, all of which could alter how the drug behaves.
What patients with fatty liver disease should do right now
For the millions of people living with MASH or its precursor, metabolic dysfunction-associated steatotic liver disease (MASLD), the immediate practical guidance has not changed. Gradual weight loss of 7 to 10 percent of body weight remains the intervention with the strongest evidence for reducing liver fat, inflammation, and even fibrosis. Improved diet quality, regular physical activity, and close management of blood sugar, blood pressure, and cholesterol form the backbone of care.
Patients who suspect they may have fatty liver disease should talk to a hepatologist or primary care physician about screening, especially if they have type 2 diabetes or metabolic syndrome. Off-label prescribing of formoterol based solely on animal data would expose patients to uncertain risks without clear evidence of benefit.
The formoterol story is worth watching precisely because the drug is old, cheap, and biologically plausible. But the question that matters most, whether this decades-old asthma medication actually makes human livers healthier and more resilient over the long term, can only be answered by the trials that have not yet been run.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
